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Abstract
Implementation and adherence to screening recommendations of Type 2 Diabetes (T2D) clinical
practice guidelines are associated with earlier diagnosis and treatment. Standardized T2D
screening helps ensure consistency of care and decrease unnecessary testing by targeting those at
greatest risk for developing the disease. The aim of this quality improvement pilot project was to
facilitate standardized T2D screening of inmates within a correctional system. The number and
frequency of selected preexisting major T2D risk factors identified within a sample of inmates
diagnosed during incarceration were described. A clinical panel reviewed these data and
identified the guideline that best addressed T2D risk in the sample. Implementation of guideline
screening recommendations as a prospective quality improvement study in a broader sample was
proposed prior to considering statewide application.

Keywords: diabetes, screening, inmates, prisoners, corrections

Diabetes Screening in Inmates: A Quality Improvement Pilot Project

Mary Ellen Castro

B.S.N., Western Connecticut State University, 1988
M.S.N., Western Connecticut State University, 1995

A Dissertation
Submitted in Partial Fulfillment of the
Requirements for the Degree of Doctor of Nursing Practice
at the
University of Connecticut

2014

Copyright by

Mary Ellen Castro

ii

iii.

DEDICATION

I dedicate this effort to the One who loves, forgives, awakens, enlightens, guides, teaches,
nourishes, shapes, protects, strengthens, and saves us.

iv.

ACKNOWLEDGEMENTS
I express my deepest appreciation the dean and faculty of the University Of Connecticut
School of Nursing, my dissertation committee, my colleagues and fellow students, my family,
and many others who guided, encouraged, and supported me throughout my dissertation.
I am most grateful to Dr. Cusson for her impassioned effort to bring the Doctor of
Nursing program to Connecticut and to Dr. Bellini for her work in initiating and leading the
program. I am equally grateful to Dr. Panosky who provided much needed support and
constructive feedback in her role as major advisor and to Dr. Shelton who helped me plan and
develop the project and mentored me in her role as my previous major advisor. I am also
grateful to Dr. Colbert, Dr. Diaz, Dr. Buchanan, and Ms. Casey, who as dissertation committee
members, provided inspiring feedback and suggestions which added depth to the work that was
evolving. I am also grateful to Dr. Walsh for his expert and enthusiastic instruction of research
and for his time and patience in helping me understand statistical concepts and also to Dr. Feinn
who thoughtfully reviewed and commented on my project design, methodology, and data. My
gratitude further extends to other faculty and staff I was blessed to learn from. These include Dr.
Kenefic, Dr. VanHoof, and Ms. Banfi.
I am most thankful to my husband and family for their unwavering love and patience and
for their sacrifice in relinquishing my time with them so that I might concentrate on my studies. I
am also thankful to my colleagues and fellow students for their unflagging encouragement and
sense of humor. Finally, I am most appreciative for the many prayers of priests, sisters, family
members, and others as they gave me hope and supported me as I persevered to complete and
defend my dissertation.
v.

TABLE OF CONTENTS

Chapter 1: Introduction ……………………………………………………………………

1

Purpose ……………………………………………………………………………......

3

Problem ……………………………………………………………………………….

3

Theoretical Framework ……………………………………………………………….

4

Screening as a Health Promotion Activity ……………………………………

6

Assumptions ……………………………………………………………………….....

6

Pilot Project Questions ……………………………………………………………….

7

Definition of Terms …………………………………………………………………..

7

Summary ……………………………………………………………………………...

8

Chapter 2: Review of the Literature ……………………………………………………….

10

Type 2 Diabetes Screening …………………………………………………………...

10

National Prevalence of Diabetes and Major Risk Factors in Inmates ………………..

14

Diabetes …………………………………………………………….………… 15
Aging …………………………………………………………………….…… 20
Overweight and Obesity ……………………………………………….……..

20

Hypertension ……………………………………………………………….…

20

Coronary Vascular Disease and Dyslipidemia ……………………………….. 22
Impaired Fasting Glucose (Prediabetes) ……………………………………...

23

Physical Inactivity …………………………………………………………….

24

Race …………………………………………………………………………... 25

vi.

TABLE OF CONTENTS

Cost-Effectiveness ……………………………………………………………………

25

Summary………………………………………………………………………………

28

Chapter 3: Methods ………………………………………………………………………...

31

Population and Sample ………………………………………………………….……. 31
Inclusion Criteria ……………………………………………………………….…….. 31
Exclusion Criteria …………………………………………………………………….

31

Sample Size …………………………………………………………………………...

32

Design ………………………………………………………………………………...

33

Instrument Development ………………………………………………………….….

33

Clinical Guidelines ……………………………………………………………

34

Data Collection Instrument …………………………………………………..

36

Institutional Approval ………………………………………………………………...

38

Protection Against and Minimization of Risks ………………………………

38

Protections Pertaining to Prisoners as Subjects ………………………………

39

Procedure ……………………………………………………………………………..

39

Privacy ………………………………………………………………….…….

39

Confidentiality of Data …………………………………………………….…

40

Data Management …………………………………………………………………….

41

Data Collection ....…………………………………………………….………

41

Data Cleansing ………………………………………………………………..

44

Data Analysis …………………………………………………………………

44

vii.

TABLE OF CONTENTS

Generalization and Predictions ……………………………………………………….

45

Summary ……………………………………………………………………………..

45

Chapter 4: Results ………………………………………………………………………….

46

Results ………………………………………………………………………………..

46

Clinical Panel Findings ……………………………………………………………….

50

Clinical Guidelines …………………………………………………………………… 50
The Federal Bureau of Prisons Diabetes Practice Guidelines ……………….

50

The American Diabetes Association Standards of Care ……………………...

51

The National Commission on Correctional Health Care Diabetes
Management Guidelines …………...…………………………………………

52

Summary ……………………………………………………………………..

55

Chapter 5: Discussion and Summary ……………………………………………………..

56

Discussion of Findings ………………………………………………………………..

57

Limitations ……………………………………………………………………………

60

Implications and Recommendations ………………………………………………….

62

Summary ……………………………………………………………………………...

63

References ……………………………………………………………………………………

65

Appendices …………………………………………………………………………………..

78

Appendix A: Data Collection Instrument ……………………………..……………

78

Appendix B: Body Mass Index Graph ………………………………………………

79

Appendix C: Department of Correction Project Approval ………………………….

80

viii.

TABLE OF CONTENTS

Appendix D: Institutional Review Board Project Approval …………………………

81

Appendix E: Institutional Review Board Project Continuation Approval …………..

82

ix.

Running head: DIABETES SCREENING IN INMATES

1

Chapter One
Type 2 diabetes (T2D) is a major national health problem accounting for 90 to 95% of all
diagnosed diabetes cases in adults (CDC, 2011). With an aging population and increasing rates
of obesity and sedentary lifestyles, the national incidence of T2D is increasing (Koller, Chin, and
Conway, 2013). Diabetes prevalence in correctional settings is predicted to increase as the
population of inmates serving long sentences ages and new inmates who are at risk for T2D are
incarcerated (ADA, 2011a, 2013a). Due to poor health habits and limited access to health care
prior to incarceration, inmates having T2D might be unaware they have the disease when they
enter the correctional system (Dumont et al., 2012). Others could have risk factors for T2D and
develop the disease during incarceration. Inmates with unrecognized T2D are not afforded early
treatment or education interventions that might control diabetes progression and potentially avert
complications (Weber, Twombly, Narayan, and Phillips, 2011).
Type 2 diabetes has a gradual progression and it is estimated that 10% to 23% of those
with impaired fasting glucose (prediabetes) develop T2D within five years of diagnosis (Rich et
al., 2013.) Type 2 diabetes screening helps identify those who are at increased risk for
developing the disease and may benefit from diagnostic testing and health education
interventions aimed at normalizing glucose regulation (ADA, 2011a, 2013a; Perreault et al.,
2012). Those not identified at risk for T2D might not receive these interventions (Chamnan et
al., 2012; Murphy and Winmill, 2013).
Diabetes imposes an increasingly significant healthcare burden. Estimated total United
States diabetes expenditures increased 41 %, from $174 billion in 2007 to $245 billion in 2012,
and are predicted to rise in tandem with increased prevalence projections (ADA, 2013c).
Although diabetes expenditure data has not been reported by correctional systems, as care is
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constitutionally commensurate with that of the community, the impact of diabetes on
correctional budgets is believed to be major (ADA, 2009; Kinsella, 2004). Delayed diagnosis
and treatment of T2D in inmates can result in costly comorbid conditions which burden not only
correctional systems, but the community, as the majority of inmates are eventually released
(Chettiar et al., 2012; Williams et al., 2012). Type 2 diabetes screening in inmates may reduce
these expenditures (Lee et al., 2010; Tomlinson and Schechter, 2002).
Implementation and adherence to T2D screening recommendations of correctional
diabetes clinical practice guidelines (CPGs) are associated with earlier diagnosis and treatment
(ADA, 2013b). Adherence to guidelines promotes a culture of patient safety and is a
recommended performance measure to assess correctional health care services (Greifinger, 2012;
Stern, Greifinger, and Mellow, 2010). Although T2D screening in inmates is recommended by
the National Commission on Correctional Health Care (NCCHC), Federal Bureau of Prisons
(FBOP), and the American Diabetes Association (ADA), not all inmates who might benefit may
be screened (Binswanger, Krueger, and Steiner, 2009; Tomlinson and Schechter, 2002). As
correctional diabetes screening recommendations vary, unless one guideline is selected to
standardize care within a correctional system, prescribers might be uncertain as to which of
several guidelines to follow (CDC, 2010; Spencer, 1999). Others may question the method by
which the diabetes CPGs from which screening recommendations were derived had been
developed (Casagrande, Cowle, and Fradkin, 2013; Lawler, 2009; Muhlhauser and Meyer,
2013).
Screening for diabetes and other chronic diseases can help identify those who might
benefit from diagnostic testing, quantify those at risk for disease, and anticipate future health
care service needs (ADA, 2011a, 2013a; Mears and Cochran, 2012). Although direct screening
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costs are estimated to be at least partially offset by a simultaneous reduction in future diabetic
complication expenses, unrecovered expenditures associated with negative tests results can be
difficult to support (Tomlinson and Schechter, 2002). Implementation and adherence to
screening guidelines that target screening to those who might benefit most can reduce costs
associated with over- or under screening (Chatterjee, et al., 2013: Dans et al., 2011; Rich et al.,
2013). In addition, the selection of one T2D screening guideline for state wide implementation
could improve consistency of care, decrease targeting errors, and reduce the risk of missing those
who might benefit from screening.
Purpose
The purpose of this quality improvement pilot project was to facilitate standardized T2D
screening of inmates within a correctional system, specifically, to describe the number and
frequency of selected major T2D risk factors in a sample of inmates diagnosed with T2D during
incarceration, for review by a clinical panel tasked with identifying the guideline screening
recommendations that best addressed T2D risk in the sample.
Problem
Delayed diagnosis and treatment of T2D can result in costly comorbid conditions which
burden not only correctional systems, but the community, as the majority of inmates are
eventually released (Chettiar et al., 2012; Williams et al., 2012). Targeted screening can
identify those at increased risk for developing diabetes and who might benefit from diagnostic
testing, interventions aimed at preventing diabetes, and early treatment to prevent disease
progression if diabetes is subsequently found (ADA, 2011a, 2013a; Perreault et al., 2012; Weber,
et al., 2011). Diabetes screening in inmates is recommended by correctional diabetes
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management guidelines, but not all inmates who might benefit are screened (Binswanger,
Krueger, and Steiner, 2009; Tomlinson and Schechter, 2002).
In the absence of being guided to utilize one correctional screening guideline within a
system, practice among correctional health providers may be inconsistent. Variations can result
in delayed or over-testing, both of which can generate unnecessary costs. Differences in
screening approaches can also make it more difficult to complete disease prevalence and
therapeutic control comparisons necessary for evaluation and reporting purposes (Borysova et
al., 2012). In addition, variations in T2D screening practice could potentially invite malpractice
litigation.
The selection of a T2D screening guideline should consider the population to which it is
intended to apply. In an effort to limit screening to those who might benefit most and realize
potential cost savings, screening those at greatest risk for developing T2D is advocated
(Chatterjee et al., 2013). However, care must be taken to not exclude a substantial number of
those who might also benefit from screening (Casagrande et al., 2013; Sheehy et al., 2010).
Without a description of the number and frequency of retrievable T2D high risk factors within an
inmate population, the guideline selected for implementation may be inappropriate.
Theoretical Framework
The theoretical framework selected for this pilot project is rooted in the preventive
maintenance philosophy of Leavell and Clark (1953). Although this framework is not as current
as other frameworks, it is still relevant because its health promotion precepts specifically address
the focus of this project - diabetes screening.
From an epidemiological perspective, Leavell and Clark (1953) expanded upon existing
preventive medical knowledge to increase disease prevention and health promotion awareness.
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Disease was perceived as a dynamic process that follows a natural progression and involves
environmental interaction. Leavell and Clark (1953) defined preventive medicine as “the science
and art of preventing disease, prolonging life, and promoting physical and mental health and
efficiency” (p. 7). Effective preventive medicine was viewed as halting disease progression as
early as possible, studying causes and effects, recognizing contributory environmental factors,
and implementing interventions to impede or stop the advancement of disease or disability.
Within the framework of preventive medicine, five primary levels of prevention were
identified: health promotion, specific protection, early recognition and prompt treatment,
disability limitation, and rehabilitation (Leavell and Clark, 1953). Health promotion concerned
efforts directed to promote overall wellness and included promotion of appropriate nutrition and
adequate exercise. Specific protection was deemed the primary focus of preventions intended for
individuals and focused on preventing disease. Early disease recognition and prompt treatment
were meant to prevent or cure a condition when possible, halt disease progression and prevent
complications, and limit the duration of impairment. Disability limitation referred to the delay of
complications associated with advanced disease states. Rehabilitation consisted of physical,
mental, and social aspects of care that would prevent total disability and enable the person to
contribute usefully to society.
Leavell and Clark (1953) considered screening a health promotion activity as it
heightened awareness of modifiable factors associated with the onset of a specified disease. An
underlying premise to screening was that disease followed a natural progression during which
signs warranting further evaluation might be identified. This evaluation would either exclude the
presence of the disease state or lead to diagnosis. Early diagnosis and management of disease
was deemed essential to preventing its progression and any disabling comorbidity.
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Screening as a Health Promotion Activity. Leavell and Clark (1953) noted that
patients who had been diagnosed with diabetes and received appropriate treatment in the early
stages of disease had better outcomes than those diagnosed at later stages of disease progression.
Successful therapeutic interventions included the promotion of nutrition and other health hygiene
activities through patient education. The prevention and timely management of diabetes-related
complications were believed to decrease disability and lessen socioeconomic burden. Based on
their observations, Leavell and Clark (1953) asserted that diabetes was one condition for which
screening could and should be done. Their early preventive medicine precepts are congruent
with current Healthy People 2020 goals and objectives.
Healthy People 2020 goals include the attainment of high quality and longer lives
through the prevention of disease, disability, injury and death for all population groups (U.S.
Department of Health and Human Services, 2010). Prevention initiatives which reduce the
incidence and socioeconomic burden of diabetes and improving quality of life of those with or at
risk for the disease are advocated. Primary prevention objectives address increasing the
proportions of people at risk for diabetes who report increased physical activity, attempted
weight loss, and reduction in dietary fat or calories. Secondary prevention objectives include
increasing the proportions of adults screened for diabetes and then enrolling found to have
diabetes enrolled in formal diabetes education programs. Tertiary prevention objectives stress
increasing the proportion of diabetics achieving normal glucose control and decreasing the
proportion of those with diabetes-related complications.
Assumptions
1. Targeted T2D screening identifies inmates who might have the disease and may
benefit from subsequent diagnostic testing and future inmate health education programs.
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2. The selection of screening recommendations of one guideline for systemic use can
reduce the risk for inappropriate or unnecessary, duplicative, or missed T2D screening in those
who might benefit.
3. Standardized T2D screening may decrease expenditures associated with unnecessary
screening or conditions associated with delayed diagnosis.
Pilot Project Questions
1. What is the number and frequency of selected preexisting major T2D risk factors in a
sample of adult male inmates diagnosed with diabetes during incarceration within one state
correctional system?
2. Which correctional diabetes guideline screening recommendations best addresses T2D
risk in the sample?
Definition of Terms
Type 2 diabetes (T2D).
Theoretical: “A metabolic disorder characterized by chronic hyperglycemia with
disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin
secretion, insulin action or both” (WHO, 2003, p. 1), specifically, measured glycosylated
hemoglobin (HgbA1c) of 6.5% or more or serum Fasting Blood Glucose (FBG) of 126 mg/dl or
more (ADA, 2013a; ADA, 2013b.
Operational: Type 2 diabetes diagnosis documented in the inmate health record by the
correctional physician, nurse practitioner, or physician assistant.
Major type 2 diabetes (T2D) risk factors.
Theoretical: A condition or attribute strongly associated with the development of T2D.
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Operational: Age > 45; BMI >25; systolic blood pressure (SBP) >140 or diastolic
blood pressure (DBP) >90 or currently prescribed antihypertensive therapy; three or more
consecutive treated or untreated SBP measurements of >135 or DBP > 80; fasting high density
lipoprotein level (HDL) < 35 or fasting serum triglyceride level >250 mg or currently prescribed
lipid lowering therapy; history of impaired fasting glucose/prediabetes (HgbA1c of 5.7 to 6.4 or
FBG of 110 to 125 mg/dl); being of black, Hispanic/Latino, Native North American, or Asian
descent; or coronary vascular disease.
Inmates with type 2 (T2D).
Theoretical: Inmates diagnosed with T2D.
Operational: Inmates who are currently prescribed oral medications to treat T2D and
have a documented diagnosis of T2D in the inmate health record.
Screening.
Theoretical: The process whereby asymptomatic individuals who have not sought care
for a specific health problem for whom detection might benefit are found to have the problem
(WHO, 2003).
Operational: The act of testing non-diabetic inmates who are asymptomatic for T2D to
determine if there is a possibility that they might have the disease.
Summary
The prevalence of T2D in correctional settings is predicted to increase as the population
of inmates serving long sentences ages and new inmates who are at risk for T2D are
incarcerated. Those not identified at risk for T2D might not receive interventions aimed to
prevent or decrease morbidity and mortality. Screening can identify those at risk for T2D as well
as those who might benefit from diagnostic testing. Guidelines help target screening to those
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who might benefit most while decreasing unnecessary expenditures. As the prevalence of T2D
risk factors can vary between populations, it was appropriate to identify the number and
frequency of selected major T2D risk factors within a sample of adult male inmates within the
correctional system to ascertain if screening could be targeted to specific risk factors. A clinical
panel reviewed these data and identified the guideline that best addressed T2D risk in the sample.
Implementation of guideline screening recommendations as a prospective quality improvement
study in a broader sample was advised prior to considering statewide application.
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Chapter Two
Diabetes screening and management guidelines are associated with improved clinical
outcomes (Giorda et al., 2012). Adherence to guidelines promotes a culture of patient safety and
is a recommended performance measure to assess correctional health care services (Greifinger,
2012; Stern et al., 2010). Implementation and adherence to guidelines target screening to those
who might benefit most and reduce costs associated with unnecessary screening (Dans et al.,
2011; Rich et al., 2013).
A comprehensive search of the 2003-2013 literature conducted using PubMed, CINAHL,
Medline, and Google Scholar databases for “diabetes AND screening AND inmates (OR prisons
OR jails OR corrections” found no empirical research reported on this topic. Consequently, this
review of the literature examined research pertaining to theoretical and empirical support of T2D
screening and empirical evidence reporting the prevalence of T2D and selected major risk factors
within the correctional population.
Type 2 Diabetes Screening
Justifications for T2D screening include the increasing prevalence of the disorder, the
recognized asymptomatic nature of incipient diabetes, the substantial number of individuals with
T2D who are undiagnosed and unaware of a need for intervention, and a long preclinical period
in which detection can occur (World Health Organization [WHO], 2003). During this time,
interventions aimed at preventing or delaying the onset of T2D can be initiated. WHO (2003)
reports that early diabetes detection and treatment can increase the length and/or quality of life,
reduce costs associated with diabetes complications, and help reallocate these expenditures to
competing priorities. These precepts are congruent with Leavell and Clark’s (1953) Preventive
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Medicine framework and Healthy People 2020 objectives (U. S. Department of Health and
Human Services, 2010).
Justifications for T2D screening are supported by findings of the Diabetes Prevention
Program (DPP) (The Diabetes Prevention Program Research Group [DPPRG], 2002) and the
Diabetes Prevention Program Outcomes Study (DPPOS) (Perreault, et al., 2012). The DPP study
was conducted to determine if lifestyle intervention (diet and exercise) or metformin therapy
might decrease T2D risk in a sample (n=3,234) of pre-diabetic obese individuals (DPPRG,
2002). Participants from 27 clinical sites across the United States were followed for an average
of 2.8 years (DPPRG, 2002, p. 393). Sixty-eight percent of the subjects were female and the
mean age of the sample was 51. Forty-five percent of the sample belonged to a racial or ethnic
minority group (20% African American, 16% Hispanic, 5% American Indian, 4% Asian or
Pacific Islander). At the conclusion of the study, it was reported that those who adhered to the
lifestyle intervention regimen had decreased T2D risk by 58 percent; those who adhered to the
Metformin regimen decreased T2D risk by 31 percent (DPPRG, 2002, p. 393).
Eligible study DPP participants (n=2,846) were subsequently enrolled in the ten year
follow-up DPPOS (Perreault et al. (2012). Among those who had continued lifestyle
intervention, T2D incidence was decreased by 43 percent; among those who continued
Metformin therapy, T2D incidence was decreased by 18 percent (Perreault, et al., 2012). As the
DPP and DPPOS were conducted in the United States and included a significant sampling of
racial ethnic minority populations, these findings may be useful to support ongoing T2D
screening and interventions to decrease T2D risk in correctional settings having similar racial
ethnic inmate characteristics.
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In addition to the DPP and DPPOS findings, WHO T2D screening precepts were also
supported by a regression analysis which associated improved cardiovascular outcomes and
lower all-cause mortality with the implementation and adherence of a diabetes screening and
management guideline within an Italian national healthcare setting (Giorda et al., 2012). In
contrast to these findings, those of other European studies differed.
The Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen Detected
Diabetes in Primary Care (ADDITION) was the first large multi-national randomized
intervention study investigating the response to intensive intervention to reduce morbidity and
mortality in those diagnosed with T2D following screening (Griffin et al., 2011). Screening was
targeted using age, gender, BMI, hypertension, and steroid use criteria. Subjects had previous
access to national health care services health care. Fifty-eight percent of the subjects were male
and the mean age of the sample was approximately 60 years (Sandback et.al., 2008, p. 30).
Subjects who were not Caucasian (white) comprised 5 percent of the sample (Sandback et.al.,
2008, p. 30).
Comparing the effect of early intensive interventions against usual care in the
management of screen detected T2D, researchers for the ADDITION-Europe (n=3057) and
ADDITION- Denmark (n=1533) arms of the study reported that those who received intensive
intervention had a small and non-significant reduction in cardiovascular events over 5 and 6
years respectively (Charles, et al., 2013; Griffin et al., 2011). Findings for the ADDITIONCambridge (n=20,184) arm suggested that compared with usual management of screen detected
T2D, intensive intervention did not significantly reduce cardiovascular or all-cause mortality
over 10 years (Simmons et al., 2012). As both those in the intensive and normal care groups in
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all arms of the study received appropriate care, it would be premature to abandon T2D screening
recommendations based solely on these findings.
In addition, as it was not possible to have included a no-treatment group, the benefits of
intensive or usual care against no care, could not be quantified. It was also not known if findings
would have varied in a different predominant racial/ethnic group. Therefore, ADDITION study
results should be interpreted cautiously by United States correctional systems having inmate
population characteristics different from ADDITION samples.
Under the premise that the characteristics, progression, and potential complications
associated with diabetes meet criteria for which screening is appropriate, T2D screening of
individuals at risk is recommended (ADA, 2011a, 2013a; WHO, 2003). National correctional
professional practice standards recommend diabetes screening in inmates to improve diabetes
outcomes and help prevent comorbidity (ADA, 2008b, 2013b; FBOP, 2010; 2012; NCCHC,
2009, 2013).
In the resource-sensitive correctional environment wherein pressing safety and security
concerns may supersede healthcare ideals, prioritization of efforts to manage acute and known
health problems is not uncommon. Although costs related to T2D screening are estimated to be
at least partially offset by simultaneous reductions in expenses related to the treatment of
diabetes related complications, unrecovered costs related to negative tests results can be difficult
to justify (Tomlinson and Shechter, 2004). Initiating evidence based measures to help decrease
the number of costly negative test results is warranted. There is some support to begin universal
T2D screening in the community starting between ages 30 and 45 (Kahn, et al., 2010). Although
universal screening is believed to be more cost-effective than not screening, greater benefit is
believed to be attained through a targeted approach (Chatterjee, Narayan, Lipscomb, and
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Phillips, 2010). Investigating cost-effectiveness of T2D screening in hypertensive and general
populations, Hoerger et al. (2004) found that targeted screening would be more cost-effective
than universal screening and that screening of individuals between 55 and 75 of age would be
most efficacious. Other research suggests that screening would benefit those 45 and older who
are at above average risk for T2D (Gillies et al., 2008).
The review of the literature found no findings that clinical research has been conducted to
study the benefits of T2D screening in inmates. WHO and ADA advocate T2D screening in all at
risk populations under the premise that reductions in long-term complications and
socioeconomic costs would be achieved (CDC, 2010). The U.S. Preventive Services Task Force
(USPSTF) analyzed data from previous studies to investigate if screening and early detection and
treatment of T2D improved healthcare outcomes (2008). Based on its review, USPSTF found
that although aggressive treatment of hypertension in diabetics reduced cardiovascular
complications by 50%, there was no evidence to support that earlier T2D detection improved the
outcomes of those with diabetic visual impairments or renal compromise.
National Prevalence of Diabetes and Major Diabetes Risk Factors in Inmates
Due to variations in correctional system data collection and tracking methods used to
report disease incidence in United States correctional settings, accurate national prevalence data
may be lacking. When only 19 of 41 states responded to a NCCHC survey for its 2004 report,
The Health Status of Soon-to-Be Released Inmates, reported that they collected prevalence data
on diabetes, hypertension, heart disease, or asthma, prevalence data needed to be estimated from
the community population (Lincoln, et. al., 2010, p. 513). Although the capabilities of welldesigned electronic health records (EHRs) can facilitate the collection, tracking, and reporting of
disease prevalence data based on documented diagnoses, the majority of state correctional
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systems have not yet implemented them (Bisset and Harrison, 2012; Woodward, 2010).
Consequently, the United States national prevalence of diabetes and major diabetes risk factors
in inmates has been based on self-report surveys and prevalence projection studies. Comparative
community prevalence estimates provide useful reference information, and these data were
included in the review of studies that reported these data. As the literature estimating the
prevalence of major diabetes risk factors was predominantly found in studies estimating diabetes
prevalence, study design and strengths and weaknesses were the same for all content within these
studies.
Diabetes. To help understand the impact of chronic diseases on correctional and
community health systems, Hornung, Greifinger, and Gadre (2002) used a projection model to
estimate the prevalence of medical conditions including diabetes. These researchers selected
data from the third National Health and Nutrition Examination Survey (NHANES-III), which
had been obtained from laboratory findings and based on established diagnostic criteria, as the
community population reference standard to estimate disease prevalence. Specific age-adjusted
gender and race/ethnicity rates for the U. S. population age 17 and older was derived from 1990
U.S. Census data and applied to 1995 National Institute of Justice (NIJ) jail and prison inmate
population estimates (Hornung, Greifinger, and Gadre, 2002, p. 40). Application of NHANESIII data to inmate population estimates was done to estimate disease prevalence in inmates.
A second analysis was undertaken to estimate disease prevalence in the subgroup of
inmates who belonged to the low socioeconomic (SES) group believed to be most representative
of the inmate population (p. 40). Calculations for both analyses were based on weighted 1995
national criminal justice prison population statistics (which may not have been representative of
the state correctional system where this pilot project was conducted). Diabetes prevalence
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estimates were made based on the fasting serum glucose > 140 mg/dL diabetes diagnostic
criterion accepted when NHANES-III was conducted (1988 to 1994) as well as that revised
standard which was adopted in 1997 and lowered fasting serum glucose to > 126 mg/dL.
Based on the > 140 mg/dL or greater fasting serum glucose diagnostic criterion, it was
estimated that 4.9% of community, 3.0% of federal prison inmates, 2.0% of state prison inmates,
and 1.8% of local jail inmate populations had diabetes. Adjusted diabetes diagnostic criterion to
fasting serum glucose 126 mg/dL or greater increased prevalence estimates to 7.6, 5.2, 3.3, and
3.0% respectively. Diabetes prevalence was generally estimated to be higher in the low SES
subgroups. In each analysis, diabetes prevalence was estimated to be higher in the community
than the correctional setting. Diabetes estimate differences between inmate populations were
attributed to variation in age demographics.
A major strength of the study undertaken by Hornung et al. (2002) was the use of a
diabetic community reference standard that had been based on objective findings and established
diagnostic criteria. Through this and the application of essential demographic data, more accurate
estimates of diabetes prevalence were made. However, the precision of estimate projections was
compromised by the inability to account for behavioral and education preparation factors linked
to health habits and that possibly differ between community and correctional populations.
A different approach to estimate the prevalence of chronic diseases was undertaken by
the U.S. Department of Justice’s Bureau of Justice Statistics (BJS). Specifically, the collection
and analysis of jail and prison inmate survey data in the 2002 Survey of Inmates in Local Jails
(SILJ) which was published in the 2006 Medical Problems of Jail Inmates report and the 2004
Survey of Inmates in State and Federal Correctional Facilities (SISFCF) (BJS, 2007; James,
2004; Maruschak, 2006). According to health information obtained as part of SILJ, 2.7% of jail
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inmate respondents (n=5872) self-reported diabetes (James, 2004; Maruschak, 2006). Prevalence
increased with age, ranging from 0.6% of inmates in the 24 or younger age group to 8.4% of
those 45 or older. Estimates were higher among respondents to SISFCF. In this survey, 4% of
state (n=12,846) and 5.1% of federal (n=3,119) prison inmates self-reported diabetes. Similar to
SILJ findings, diabetes prevalence increased with age, with prevalence in state prisons ranging
from 0.4 % in inmates age 24 or younger to 11.3 % in those 45 and older, and prevalence in
federal prison ranging from 0.7 % to 12.9 %. Comparing overall prevalence estimates between
SILJ and SISFCF, diabetes prevalence was lowest in local jail (2.7%) and highest in federal
prison (5.1%) inmate populations. The observation that these prevalence estimates, which were
based on self-report data are lowest among inmates incarcerated in local jails and highest in
those remanded to federal prisons, is consistent with that made by Hornung et al. (2002) using
their projection model.
Primary strengths of both SILJ and SISFCF surveys included large national sampling,
relevant and comprehensive data collection, and a superior response rate that exceeded 84%. A
significant limitation to the SILJ and SISFCF was the inability to validate inmate responses to
questions about disease states through confirmatory diagnostic testing. Another major limitation
was the potential for measurement errors due to under- or over-reporting of health conditions.
Reasons for doing so include unfamiliarity with terms used to describe a health condition,
misapprehension regarding the purpose or use of the survey, mistrust of those who obtain or
review responses, literacy or processing deficits, and language barriers. Inmates might also be
unaware of having a medical condition as screening or diagnosis prior or during incarceration
might not have been done.
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Wilper et al. (2009) analyzed SILJ and SISFCF sample data in order to formulate
prevalence estimates for chronic diseases. Sample weights supplied by BJS were applied to
account for nonresponse and survey design and yield national correctional estimates (Wilper, et
al., 2009, p. 668). Age-adjusted comparisons were then made with 2003-2004 National Health
and Nutrition Examination Survey III (NHANES-III) community estimates. Following analysis
of the inmate sample inclusive of non-respondents, it was estimated that 11.1% of those
(n=3,686) in federal prisons, 10.1% of those (n=14,499) in state prisons, and 8.1% of those
(n=6982) in local jails had diabetes. By applying age-standardization to 2000 U.S. census data,,
not only were the correctional population prevalence estimates appreciably higher than those
reported in earlier studies, but they also exceeded the 6.5% community diabetes prevalence
estimate based on NHANES-III data (Wiper et al., 2009, p. 688). The latter finding differs from
the Hornung et al. (2002) estimate of greater diabetes prevalence in the community population.
Similar to previous research, among correctional populations diabetes prevalence was
estimated to be lowest in jail inmates and highest in federal prison inmates. According to a
comparison of SILJ and SISFCF demographic data by Wilper et al. (2009), the percentage of
inmates 50 or more years of age was 11.1 in federal prisons, 8.6 in state prisons, and 4.2 in local
jails. As the prevalence of T2D increases with age, these data helped explain prevalence
differences between correctional settings.
The predominant strength of the investigation undertaken by Wilper et al. (2009) was the
incorporation of age-adjusted comparisons that more precisely estimated chronic disease
estimates in inmates. As prevalence estimates were greatly dependent on SILJ and SISFCF
inmate self-reporting data, the lack of confirmatory testing to validate responses would apply to
this study as well.
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Binswanger et al. (2009) estimated the prevalence of diabetes and other chronic medical
conditions by age group and between correctional settings and the community. Sample data
from SILJ and SISFCF were analyzed to estimate prevalence in jail (n=6582) and prison
(n=14,373) populations. National Health Interview Survey-Sample Audit Files (NHIS-SAF) data
from 2002, 2003, and 2004 were used as the reference sample for the community population
(n=76,597). After pooling data and weighing survey sources to ensure that non-responses had
been accounted for and estimates were representative of the target populations, logistic
regression was used to compare prevalence between populations. Prevalence was estimated by
age group—18 to 33, 34 to 49, and 50 to 65 – and predicted to increase with age. Estimated
diabetes prevalence in jail inmates ranged from 1.5% in the 18 to 33-year-old age group to
14.4% in the 50 to 65-year-old age group. Respectively, prevalence range in prison inmates
ranged between 1.6 and 15.2%. Community diabetes prevalence estimates for identical age
groups ranged between 1.1 and 11.4%. Following adjustment for race, education, place of birth,
marital status, and alcohol consumption, diabetes prevalence estimates between correctional and
community populations were found to be comparable (Binswanger et al., 2009, p. 914). This
finding is incongruent with those reported by Hornung et al. (2002) who estimated that diabetes
was more prevalent in the community population and Wilper et al. (2009) who estimated that
diabetes was more prevalent in the correctional population.
The principal strength of the research by Binswanger et al. (2009) included the
comprehensive analysis of SILJ and SISFCF demographic, behavioral, and socioeconomic
survey data. Consequently, more exact disease prevalence estimates were achieved. As was
noted in the study by Wilper et al. (2009), limitations of the SILJ and SISFCF surveys would
also apply to this research.
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Aging. As in the community, older inmates are more likely to develop T2D as well as
chronic conditions known to increase diabetes risk. The correctional population is aging as many
are serving long sentences prompted by stricter sentencing legislation enacted in the 1980s and
1990s. According to the 2009 Bureau of Justice Statistics (BJS) report, 20.0% of the total
sentenced state and federal prisoner population (n=1,613,740) was 45 years of age or more
(West, Sabol, and Greenman, 2010). Based on existing federal demographic data and sentencing
trends, it is estimated that estimate that 30% of inmates will be 50 years of age or older by 2030
(Chettiar et al., 2012). These data were collected using reliable standardized methods.
Overweight and Obesity. Overweight and obese individuals, classified as having a
body mass index (BMI) of 25 or more, are at increased risk for T2D (ADA, 2011). Although
there is abundant literature noting the increasing prevalence of obesity in the community,
research estimating the prevalence of diabetes among correctional populations is scant. As part
of their research investigating the prevalence of chronic conditions, Binswanger et al. (2009)
estimated the prevalence of overweight and obesity. Binswanger et al. (2009) estimated that
prevalence of overweight (BMI 25 to 29.9) and obesity (BMI > 30) was lowest in the 18 to 33
age group and highest in the 50 to 65 age group in each population (jail inmate, prison inmate,
and community). Overweight was estimated to be lower in the community (28.8% to 38.4%)
and higher in the prisons (40.7% to 49.8%). Conversely, obesity was predicted to be generally
higher in the community (18.4% to 29.1%) and lower among jail inmates (13.9% to 22.1%).
Hypertension. Hypertension is directly associated with the development of T2D (ADA,
2011). According to findings from the chronic disease prevalence research undertaken by
Hornung et al. (2002), hypertension prevalence was higher in the community population (24.5%)
than the overall correctional population (16.7%). At 28.6% and 18.3% respectively, this finding
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was also found among low SES groups. Between correctional groups, prevalence was lowest
among local jail inmates (14.7%) and highest among federal prison inmates within the low SES
group (21.6%).
Findings from the SILJ and SISFCF were used to estimate hypertension prevalence
within and between inmate populations. Based on SILJ data, 11.2% of all local jail inmates
reported hypertension. Prevalence increased with age and ranged from 5.3% in the 24 or
younger age group to 26.1% in the 45 or older age group (Maruschak, 2006).

Overall

prevalence among state and federal prison inmates responding to the SILJ survey was higher at
13.8 and 13.2% respectively (BJS, 2007). As was found among jail inmates, prevalence
increased with age. This ranged from 3.4% in state prison inmates age 24 or younger to 30.6% in
those 45 and older and 2.1% and 28.4% in federal prison inmates respectively.
Wilper et al. (2009) applied NHANES-III age adjusted comparisons to SILJ and SISFCF
data analyses to estimate hypertension prevalence in inmates. Contrary to the previous findings,
prevalence was estimated to be lowest in the community population (25.6%). Within the
correctional population, hypertension was estimated to be highest among state prison inmates
(30.8%) and lowest in local jail inmates (27.9%).
Binswanger et al. (2009) also estimated hypertension prevalence to be lower in the
community population Estimated hypertension prevalence in the community population ranged
from 6.9% in the 18 to 33 year old age group to 38.8% in the 50 to 65 group. Respectively,
estimated prevalence was 10.3 and 49.7% among jail inmates and 10.6 and 50% in prison
inmates. Following adjustment for race, education, United States birthplace, marital status,
employment, and alcohol consumption, estimated prevalence in the correctional population
remained higher than in the community (Binswanger et al., 2009, p. 914).
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Coronary Vascular Disease and Dyslipidemia. Although the incidence of coronary
vascular disease has been linked to preexisting diabetes, the development of T2D has been linked
to preexisting coronary vascular disease (CVD) and dyslipidemia (ADA, 2011). Although
research investigating the prevalence of dyslipidemia in the correctional population was not
found in the literature, multiple researchers estimated the prevalence of cardiovascular disorders
in inmates. Due to variations in the type of disorders studied and data collection methods, direct
comparisons between prevalence estimates are limited.
As with their diabetes and hypertension findings, Hornung et al. (2002) estimated that the
prevalence of heart disease prevalence was higher in community populations. Compared to the
general community prevalence estimate of 6.03%, it was estimated that 3.2% of the total inmate
population had heart disease. Prevalence was also predicted to be higher in community low SES
population (8.8%) than the low SES inmate population (4.7%).
Based on SILJ self-report survey data, 5.9% of jail inmates were estimated to have a
heart problem (Maraschak, 2006). Prevalence ranged between 4.4% in 24 or younger age group
to 11.7% in those 45 years of age or older. According to SISFCF self-report survey findings, the
overall prevalence estimate for heart disease in state and federal prison inmates was similar at 6.1
and 6.0% respectively (BJS, 2007). Among prison inmates, heart disease prevalence was
estimated to increase with age and be higher in state prison inmates over 45 years of age (13.3%)
than federal prison inmates in the same age group (12.8%).
Wilper et al. (2009) estimated myocardial infarction prevalence in inmates by applying
age-adjusted comparisons to SILJ and SISFCF data analyses in the same manner used in their
diabetes and hypertension research. These researchers determined that compared to the 3%
estimated prevalence in community, federal and jail inmates had significantly higher prevalence
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rates at 4.5% and 5.7% respectively. History of myocardial infarction prevalence was estimated
to be lowest among local jail inmates (2.1%).
Binswanger et al. (2009) compared the estimated prevalence of cardiovascular
disease/angina and heart attack/myocardial infarction between community, jail inmate, and
prison inmate populations. Again, sample data from SILJ and SISFCF were analyzed to estimate
prevalence in local jail and prison populations, and NHIS-SAF was used as the reference sample
for the community population. Prevalence of cardiovascular disease/angina was predicted to
increase with age across all populations and was found to be highest (4.2%) in the uppermost age
group (50 to 65). Prevalence in this age group was estimated to be lower in the community
(3.9%) and higher among local jail inmates (4.2%). As with cardiovascular disease/angina
estimates, heart attack/myocardial infarction was predicted to increase with age across all
populations and was found highest in the 50 to 65-year-old age group. Again, prevalence was
estimated to be lower in the community (4.6%) and highest in local jail inmates (6.9%).
Impaired Fasting Glucose (Prediabetes). Persons with impaired fasting glucose (110125 mg/dL), also called prediabetes, are at increased risk for developing T2D.

Only one

investigation was found to have reported impaired fasting glucose (IFG) estimates in the
correctional population. Using a projection model that applied inmate demographic statistics to
the NHANES-III community population reference standard, Hornung et al. (2002) estimated the
prevalence of IFG in correctional settings. As had been done in the development of diabetes
prevalence estimates, a second analysis was done to estimate IFG prevalence in the low SES
subgroup.
Hornung et al. (2002) projected that 7.3% of the community population and 5% of the
total inmate population had IFG. Comparing prevalence between correctional settings, it was
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estimated that 6.9% of federal prison, 4.8% of state prison, and 4.3% of local jail inmates had
IFG. Contrary to the higher diabetes prevalence rate that had been projected for the low SES
group, IFG prevalence was not estimated to be appreciably different between community and
correctional populations. Prevalence projections of IFG for the low SES community and
correctional groups were estimated at 7% and 5.2% respectively. Within the low SES
correctional group, 6.9% of federal prison, 4.9% of state prison, and 4.4% of local jail inmates
were estimated to have IFG.
Physical Inactivity. Physical inactivity is an independent biophysical risk factor for
T2D (Pederson, 2009; Stewart et al., 2005). Due to the restricted nature of correctional settings,
the type, duration, and frequency of physical activity is limited (Leddy, Schulkin, and Power,
2009). There is no standardization and variation as what might be allowed is primarily
dependent on safety and security requirements. A review of 10 court decisions involving
quantity of exercise noted that judgments usually favored the one-hour-per-day five times a week
permitted by numerous correctional settings (Lee, 1996, p. 175). Judgments concerning the
quality (n=8) and location (n=8) of activities were incongruent but generally found that prisoners
did not have a right to a specified activity type or setting (Lee, 1996). An updated review of a
larger number of court decisions would provide more current information on exercise allowances
in correctional settings.
Physical activity is further limited in older inmates with physical limitations who are
unable to participate in available exercise options. Almost 45% of prisoners over 50 years of age
and 82% of those over 65 estimated to have chronic physical limitations (Sterns, Lax, Sed,
Keohane, and Sterns, 2008). With the aging inmate population this diabetes risk factor is likely
to become increasingly significant.
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Race. Individuals of African American, Hispanic/Latino, American Indian or Native
Alaskan, Hawaiian or Pacific Islander, or Asian descent are at greater risk for T2D (ADA, 2011).
Based on 2009 U.S. Census Bureau data the composition of racial/ethnic minority groups for the
total national population was: African American, 12.9%; Hispanic/Latino, 15.8 %; Asian, 4.6%;
American Indian or Alaskan Native, 1.0% ; and Native Hawaiian or Pacific Islander, 0.2% (U.S.
Census Bureau, 2010). Based on 2009 BJS estimates, approximately 42% of sentenced prison
inmates were African American and 22% were Hispanic/Latino (West, Sabol, and Greenman.
2010).. Although BJS did not report data for other racial/ethnic groups at greater risk for T2D
risk, comparing reported estimates against those of the U.S. Census, percentages of racial/ethnic
minorities in the national correctional system were greater than those of the total national
population.
The estimated 2009 racial/ethnic minority group total reported by BJS was approximately
the same as that reported by BJS 2002. At that time, it was estimated that approximately 45% of
sentenced prison inmates were African American and 18% were Hispanic/Latino (Harrison and
Beck, 2003). As in 2009, BJS did not report statistics specific to the American Indian or Alaskan
Native, Hawaiian or Pacific Islander, or Asian populations for 2002.
Cost-Effectiveness
Several studies have studied the cost-effectiveness of targeted diabetes screening. Using
a simulation model to estimate costs and consequences of screening current and former United
States inmates at risk for diabetes and hypertension annually over twenty years, and intensive
treatment of those diagnosed, cost-effectiveness was estimated (Tomlinson et al., 2002, p. 141142).

Prevalence and duration estimates were based on NHANES-III data, diabetes incidence

on Centers for Disease Control (CDC) data, and co-morbidity estimates on data reported in
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research conducted by disease specialty organizations. It was estimated that the annual cost of
combined hypertension and diabetes screening would not exceed $15 per person and the average
annual cost of aggressive diabetes care per inmate was $1,983. Expenditure predictions for
combined hypertension and diabetes screening and aggressive diabetes care over twenty years
for the population studied were $204,817,860 and $2,822,545,288 respectively (Tomlinson et al.,
2002, p. 152-153). As it was assumed that the average inmate length of incarceration was 4.5
years, it was estimated that 63 percent of the diabetes costs, 82 percent of diabetes treatment
costs, and 75 percent of hypertension treatment costs would be incurred following incarceration
(Tomlinson et al., 2002, p. 150 and 153). Early disease identification through screening,
aggressive disease management, and patient adherence to treatment during and following
incarceration were predicted to decrease morbidity and increase life expectancy. Through these
interventions, it was estimated that 386,108 additional person-years would be attained for this
population over 20 years, with the majority of time predicted to be spent outside of prison
(Tomlinson et al., 2002, p. 152).
Based on prospective United Kingdom diabetes screening cost data, a Markov model was
used to estimate the cost-effectiveness of one-time diabetes screening against no screening in the
U.S. population. Diabetes screening targeted to those with hypertension was compared to
universal diabetes screening. Cost-effectiveness ratios based on quality adjusted life years
(QALY) were calculated incrementally by decade starting at age 35 and ending at age 75.
Estimated QALY for diabetes screening of those with hypertension who received intensive
control of diabetes and hypertension following diabetes diagnosis per decade was 0.08, 0.16,
0.22, 0.23, and 0.18 (Hoerger et al., 2004, p. 692). Comparatively, QALY estimates for
universal screening followed by intensive control of diabetes and hypertension following
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diabetes diagnosis were lower at 0.05, 0.05, 0.11, 0.11, and 0.11 respectively (Hoerger et al.,
2004, p. 694).
Cost estimates were based on quality adjusted life years (QALY) and reported in 1997
United States dollars. The estimated cost to the U. S. healthcare system per QALY for targeted
screening ranged from $87,096 at age 35 to $32,106 at age 75. Targeted screening was found to
be more cost-effective than universal screening estimates which ranged from $143,839 at age 35
to $443,433 at age 75. Targeted screening was estimated to be most cost-effective for ages 55
and greater (range: $34,375 to $32,106) and more cost-effective than universal screening across
the same age groups ($360, 966 to $443,433) (Hoerger et al., 2004, p. 695-697).
Chatterjee, et al. (2013) studied the cost-savings of screening against no screening in a
sample of 1,573 subjects.) Costs of five non-fasting screening tests (random plasma glucose
[RPG], random capillary glucose [RCG], glycated hemoglobin [HgbA1c], random
plasma/capillary glucose [GCTpl] and random capillary glucose [GCTcap] one hour after a 50
gram glucose challenge) were calculated (p. 1). Screening expenditures were based on Medicare
reimbursement tables and estimated for a three year period. Costs included direct screening
expenditures, oral glucose tolerance testing (OGTT) done subsequent to findings suggestive of
diabetes, and direct medical costs of diabetes diagnosed through testing, and false-negative test
results. Costs were also determined for no screening, universal screening, and screening targeted
to those at high risk. High risk factors in men included age >55, BMI > 35, SBP > 130, serum
triglycerides > 150, HDL <40, and family history of diabetes.
Regardless of the type screening test, universal screening was found to be more cost
effective than no screening. The overall health system costs for screening and treatment of
diabetes of the 1,573 subjects by risk factor ranged from $67,838 using RPG testing to $81,467

Running head: DIABETES SCREENING IN INMATES

28

using HgbA1c. In comparison, the cost of not screening was $95,710. Targeted diabetes
screening was found to be more cost-effective than universal screening. Screening was found to
be most cost-effective in those with a BMI of >35 (range $24,103 using GCTpl to $28,018 using
RCG), SBP > 130 (range $26,519 using GCTpl to $32,543 using HgbA1c), and age >55 (range
$26,165 using GCTpl to $34,722 using HgbA1c) (Chatterjee, et al. 2013).
Summary
This review of the literature examined research pertaining to theoretical and empirical
support of T2D screening and empirical evidence reporting the prevalence of T2D and selected
major risk factors within the correctional population. WHO (2003) justifications for T2D
screening are congruent with Leavell and Clark’s (1953) Preventive Medicine framework and
Healthy People 2020 objectives (U. S. Department of Health and Human Services, 2010).
Screening justifications were supported by DPP and DPOS findings which found T2D risk and
incidence decreased in obese pre-diabetics who adhered to lifestyle intervention or Metformin
therapy (Perreault, 2012; DPPRG, 2012). These findings may be useful to support ongoing T2D
screening and interventions to decrease T2D risk in correctional settings having similar racial
ethnic inmate characteristics.
In contrast to the DPP and DPOS findings, the European ADDITION studies did find that
outcomes had significantly improved with intensive management of screen-detected diabetes as
compared to usual care (Charles, et al., 2013; Simmons et al., 2012; Griffin et al., 2011). The
benefits of intensive or usual care against no care could not be quantified and it is not known if
findings would have varied in a population racial/ethnic group that was not predominantly
Caucasian (95%). Based on 2009 racial/ethnicity data reported by the National Bureau of Justice
(BJS), the total percentage of inmates belonging to high risk T2D racial/ethnic groups (64%)
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(West et al., 2010). For these reasons ADDITION study findings should be interpreted
cautiously by United States correctional systems with inmate population characteristics different
from ADDITION samples.
Using prevalence projection modeling and incorporating data from the 1994 NHANESIII survey, 1990 U.S. Census, and 1995 NIJ inmate population estimates, Hornung, et al., (2002)
reported that prevalence of diabetes, impaired fasting glucose (prediabetes) and heart disease
were estimated to be lower in correctional settings compared to the community. In contrast,
Bureau of Justice SILJ (2002) and SISFCF (2004) survey findings reported that more inmates
age 45 and older were incarcerated in prisons than jails. It was also estimated that prevalence of
diabetes, hypertension, heart disease, and dyslipidemia was greater in older inmates and in prison
settings. These and other BJS survey data were subsequently used by other researchers to
estimate prevalence and make prevalence projections.
Maraschuk (2006) extracted data from the BJS surveys and reported that hypertension
and heart disease increased with aging and was greater among prison inmates age 45 or more.
Applying age-standardization to prevalence data derived from SILJ, SISFCF, and NHANES-III
surveys, data, Wilper, et al. (2009) estimated that the prevalence of diabetes, hypertension, and
myocardial infarction was higher among prison and jail inmates. In their prevalence study based
on SILJ, SISFCF, and NHIS-SAF data, Binswanger et al. (2009) reported that prevalence
estimates for hypertension were estimated to be increased in prison and jail inmates, following
adjustments based on race/ethnicity and other factors, diabetes and myocardial infarction
prevalence was similar between correctional and community populations. Differences between
reported estimates may reflect intervals between time studies had been conducted or due to
variations in surveys used to make projections or data analysis. Despite differences between
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these and other estimated prevalence findings, major risk factor data may help understand the
potential risk for T2D onset in correctional populations as well as its potential impact on
correctional and community systems.
Based on a simulation model Tomlinson et al. (2002) predicted that T2D screening might
decrease T2D related morbidity and costs among current and former inmates, with the majority
of savings being realized following incarceration. Chatterjee et al. (2010) and Hoerger et al.
(2004) reported that cost savings may also be achieved through targeted T2D screening which
reduces the number of unnecessary screening tests. Apart from targeting T2D screening to
identified high risk factors, Gillies et al. (2008) found that screening targeted to those age 45 and
older who at average risk of developing T2D was beneficial. These cost savings findings support
the benefit of targeted screening in correctional systems.
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Chapter Three
This quality improvement pilot project used a retrospective descriptive study design to
describe the number and frequency of selected major T2D risk factors in a sample of inmates
diagnosed with T2D during incarceration. This methods chapter discusses the plan whereby
permission was granted to conduct the project, the sample was obtained, data was collected, and
findings were reviewed. The chapter has the following sections: 1) population and sample; 2)
design, 3) data collection instrument development; 4) institutional approval; 5) data collection; 6)
data analysis; 7) generalization and predictions; and 8) summary.
Population and Sample
On January 1, 2011, the state system’s total inmate population was approximately 17,000.
It was not known how many of these inmates had T2D prior to incarceration or how many were
diagnosed with T2D during incarceration. Based on information from the existing electronic
pharmacy database reporting the number of inmates taking oral medications commonly used to
treat T2D, it was estimated that approximately 450 adult male, less than 20 female, and less than
5 juvenile male inmates within the correctional system might have T2D. As the estimated
sample sizes of female juvenile or adult inmates and male juvenile inmates with T2D were
deemed too small to benefit the selection of a screening guideline for statewide implementation,
these populations were excluded from this project.
Inclusion criteria. For the purposes of this quality improvement pilot project, the
sample was limited to male inmates who were age 18 and older and had been diagnosed with
T2D during incarceration within the state correctional system.
Exclusion criteria. Adult male inmates who were diagnosed with T2D before
incarceration and those having a diagnosis of Type 1 diabetes, were excluded from the sample.
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Also excluded from the sample were juvenile male (age 17 and younger) and female (any age)
inmates.
Sample size. The sample for this pilot project consisted of 50 subjects. In consultation
with a doctorally-prepared statistician, this sample size was deemed adequate for this pilot
project as a descriptive design was planned (R. Feinn, personal communication, July 22, 2011).
Power analysis was deemed irrelevant as statistical inference testing was not planned (R. Feinn,
personal communication, July 22, 2011). At the time the sample size was set, it was not known
as to how many inmates might meet inclusion criteria or how many health records might need to
be reviewed to identify 50 subjects. Given this, it was anticipated that health records belonging
to inmates from at least several correctional facilities would need to be reviewed to attain the
sample size. Surprisingly, the review of 123 inmate health records, at one facility, of those who
potentially met inclusion criteria yielded 50 subjects.
After the sample size for the pilot project had been met, a negative binomial distribution
analysis was performed to estimate the prevalence rate of T2D diagnosed during incarceration
(n=50) within the sample of inmates whose health records were reviewed (n=123) and not
discarded (n=3) (S. J. Walsh, personal communication, April 21, 2013).

Based on this analysis,

40.2% of the inmates whose records were reviewed had T2D diagnosed during incarceration.
Applying an approximated standard error magnitude of less than 4.3% the statistician determined
that the confidence interval for the estimated prevalence rate was: (31.8%, 48.6). It was further
noted that based on the initial goal of finding 50 subjects for this pilot study, the properties of
negative binomial distribution guaranteed that the standard error for the estimated prevalence
rate would have been relatively precise regardless of the number (n=123) of records reviewed)
(S. J. Walsh, personal communication, April 21, 2013).
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Design
This quality improvement pilot project was implemented for the purpose of answering
two study questions:
1. What is the number and frequency of selected preexisting major T2D risk factors
in a sample of adult male inmates diagnosed with diabetes during incarceration
within one state correctional system?
2. Which correctional diabetes guideline screening recommendations best addresses
T2D risk in the sample?
In response to the first question, a retrospective descriptive design was used to describe
the number and frequency of preexisting selected major T2D risk factors in a sample of adult
male inmates diagnosed with T2D during incarceration within one state correctional facility. In
response to the second question, expert opinion was deemed essential to generating
recommendations from a clinical risk and benefit perspective (Asch et al, 2011).
Based on their clinical expertise and familiarity with the correctional population, a clinical panel
was formed to review the project’s findings. The group consisted of the medical directors of the
correctional system and the contracted health care provider and a community-based certified
diabetes educator with expertise in treating inmates following incarceration. This group was
tasked to review pilot project data against guideline screening recommendations and decide
which guideline best addressed T2D risk in the sample.
Instrument Development
A data collection instrument was developed specifically for this project to collect selected
major T2D risk factor data and related information contained within the inmate health record.
Individual instrument item content was reviewed by the medical directors of the correctional
system and the contracted health care provider to ensure congruence with the purpose of the pilot
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project and also to validate that item content clearly and accurately reflected the elements for
which data was to be collected. Risk factor information corresponded with those of T2D
guideline screening recommendations being considered for implementation. In addition to
documentation of selected risk factor information for data collection purposes, documentation of
demographic data and diabetes diagnostic information also served to facilitate the sample
selection process by helping to eliminate inmates who did not meet pilot project inclusion criteria
(Appendix A). The instrument was also designed to collect information regarding the length of
time between incarceration and T2D and the number of facilities in which an inmate was housed
prior to diagnosis. This information was requested by the Department of Correction to help plan
future inmate education programs to address reversible T2D risk factors.
Clinical Guidelines. Type 2 Diabetes (T2D) screening recommendations considered for
this pilot project were embedded within three diabetes management guidelines used in United
States correction systems: Diabetes Management in Correctional Institutions (ADA, 2011b),
National Commission on Correctional Health Care (NCCHC) Diabetes Guideline for Disease
Management in Correctional Settings (2009), and Federal Bureau of Prisons (FBOP) Diabetes
Clinical Practice Guidelines (2010). The recommendations within each of these guidelines
advocated screening of those at high risk for developing the disease. However, major risk factors
for which screening was recommended varied between guidelines.
Diabetes Management in Correctional Institutions was developed by the American
Diabetes Association (ADA, 2011b) and conformed to its Standards of Medical Care in Diabetes
used in the community (ADA, 2011a). Based on those standards, T2D would be considered in
those with a BMI of 25 or greater and with at least one additional major T2D risk factor. Major
risk factors in adult male populations also included: high-risk race/ethnicity (African
American/black, Hispanic/Latino, Asian American/Asian, Native North American, or Pacific
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Islander); current antihypertensive therapy or blood pressure of 140/90 or more; dyslipidemia
(HDL cholesterol level < 35 mg/dL and/or triglyceride level > 250/dL); cardiovascular disease;
physical inactivity; first-degree relative with diabetes; and history of impaired fasting glucose
(prediabetes) as measured by elevations in glycosylated hemoglobin (HgbA1c) of 5.7 to 6.4 or
fasting blood glucose (FBG) of 110 to 125 mg/dL measurements (ADA, 2010, p. S12). In
absence of any of the major risk factors, the ADA advised T2D screening of those who are 45 of
age or more (ADA, 2011a, p. S13).
The diabetes management guideline issued by the National Commission on Correctional
Health Care in 2009 was adapted from prior ADA guidelines (ADA, 2008a, 2008b). At a
minimum, T2D screening was recommended for inmates with a BMI >25, history of
hypertension or elevated cholesterol, or age 45 or older (NCCHC, 2009, p. 1). As these risk
factors were taken from the ADA guidelines, risk factor criteria were identical.
Conversely, 2010 Federal Bureau of Prisons (FBOP, 2010) diabetes practice guidelines
were based on prior U.S. Preventive Services Task Force recommendations and advised routine
diabetes screening only for low-risk inmates who have a treated or untreated blood pressure
greater than 135/80. Otherwise, these guidelines recommend that T2D screening should be
targeted to inmates with dyslipidemia or other disease states as clinically appropriate (FBOP,
2010; USPSTF, 2008).
The ADA and FBOP advised annual testing of those identified with impaired fasting
glucose (prediabetes) on initial screening (ADA, 2011a, 2011b; FBOP, 2010). For those with
other major T2D risk factors, repeat screening at 3-year intervals was recommended (ADA,
2011a, 2011b; FBOP, 2010). The 2009 NCCHC guideline referred to prior ADA
recommendations for guidance (ADA, 2008a, 2008b).
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Data Collection Instrument. As national correctional guidelines varied in regards to
which T2D risk factors should be considered in screening inmates, major risk factors named in
one or more guidelines, routinely documented in the health record, and retrievable by the
investigator were selected for data collection and listed on the instrument. As data pertaining to
other major T2D risk factors - specifically physical inactivity, first-degree relative with diabetes,
acanthosis nigricans - were not collected for this pilot project, these risk factors will be added to
future studies. In addition, major T2D risk factor data specific to females (i.e. history of
gestational diabetes, polycystic ovarian disease, or having delivered a baby weighing > 9
pounds) will be obtained in studies involving female inmates.
Demographic information collected for risk factor screening purposes consisted of
race/ethnicity, height and weight (which were used to measure BMI), and age at the time of T2D
diagnosis. The instrument addressed whether or not, based on the collected information, the
inmate had risk factors for T2D based on race/ethnicity (belonging to a high risk racial/ethnic
group – African American (Black), Hispanic/Latino, Native North American, or Asian), weight
(BMI of 25 or more), or age (45 or older).
As BMI was not routinely assessed or reported in the health record, but could be
determined using the last recorded height and weight documented prior to T2D diagnosis, BMI
was calculated using a standard graph (Appendix B).
The form also provided for the collection of demographic content that could be useful to
plan future inmate education programs to address reversible T2D risk factors. For the purposes
of this project, date of incarceration was defined as the initial date (month and year) of
incarceration to the state correctional system inclusive of any subsequent returns from escape or
transient out-of-state or federal custody compacts that might have occurred. Date of T2D
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diagnosis was defined as the date the correctional physician, nurse practitioner, or physician
assistant documented the condition in the inmate health record. The measured length of
incarceration prior to T2D diagnosis was inclusive of the date (month and year) of incarceration
and the date (month and year) of diagnosis. The number of facilities in which health care had
been provided during the incarceration period in which T2D was diagnosed was inclusive of the
facility where the inmate was admitted to the correctional system. This information was obtained
through the review of problem lists, clinical notes, transfer summaries, infirmary records,
laboratory records, or other health provider documentation contained within the inmate health
record.
Historical medical information was limited to selected major T2D risk factors that were
evident prior to T2D diagnosis, included on the diabetes guidelines, and documented in the
health record, in particular, history of impaired fasting glucose or prediabetes as measured by
elevations in glycosylated hemoglobin (HgbA1c) of 5.7 to 6.4 or fasting blood glucose (FBG) of
110 to 125 mg/dl measurements (ADA 2011, 2012). History of coronary vascular disease,
prescribed lipid lowering therapy, fasting high density lipoprotein (HDL) of < 35, or fasting
serum triglyceride (FST) of > 250 or more were noted. Prescribed antihypertensive therapy,
most recent documented systolic blood pressure (SBP) measurement of > 140 mm/HG or
diastolic blood pressure of > 90 mm/Hg, or history of three or more consecutive treated or
untreated SBP measurements > 135 mm/Hg or DBP measurements > 80 mm/Hg were additional
T2D risk factors named on the instrument.
Prior to submission to the correction system Research Advisory Committee (RAC) and
the Internal Review Board (IRB) of the contracted health care provider, the instrument was
reviewed by the contracted health provider’s medical director and the statistician. This was done
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to assure that demographic information and labeling of selected major T2D risk factors named in
one or more of the screening guidelines was clear, concise, and complete and contained no
identifying subject information. A recommendation by the statistician to eliminate several
duplicative data elements was followed. Subsequent to this, and prior to implementation, the
instrument was reviewed by members of the RAC and IRB committees. An IRB
recommendation to use a list of simple ordinal numbers (1, 2, 3 …) instead of a random number
table for subject identification was made.
Institutional Approval
Approval to conduct this quality improvement pilot project was obtained from the
Research Advisory Committee (RAC) of the correctional system. Following RAC approval,
institutional approval was obtained from the Internal Review Board (IRB) of the contracted
healthcare provider. Both approval documents were thereafter sent to the University of
Connecticut IRB for its review and approval. Project modification was granted by the contracted
healthcare IRB, and reciprocal approval was granted by the University of Connecticut IRB (IRB
Number: 12-027S-2). Project continuation was granted by the contracted healthcare IRB, with
reciprocal approval by the University of Connecticut IRB.
Protection Against and Minimization of Risks. This quality improvement pilot project
consisted of non-experimental procedures (retrospective health record reviews) minimizing risks
to subjects. Alternative options had included experimental testing, specifically fasting blood
glucose (FBG) or two-hour oral glucose tolerance testing (OGTT). Risks of FBG screening
included discomfort and potential for trauma/infection associated with phlebotomy. Risks of
OGTT screening included safety and security issues associated with changes in custody routine
to accommodate the testing period and costs to inmate workers who would have been unable to
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work for the hours or the day of testing. Expenditures (FBG = $23 per test; OGTT = $36 per
test) associated with testing analysis would have been difficult to justify in cases of normal test
results (Healthcare Blue Book, 2013).
Protections pertaining to prisoners as subjects. The nature and scope of this quality
improvement pilot project limited its findings to the correctional facility where the sample was
obtained. As there was no experimental testing, risks to subjects were minimal. As the project
was limited to the review of health records of inmates diagnosed with T2D during incarceration,
the findings of this project have the potential to benefit other inmates who might be at risk for the
disease and could benefit from early diabetes detection and health education. Timely and
appropriate T2D management and health promotion activities may decrease overall department
health care costs and benefit the community at large.
As confidentiality and risk for protected health information disclosure need to be
protected in both inmate and community populations, the risks involved in this project were
commensurate with those that would have been accepted by non-prisoner volunteers. Deidentified data from inmate health records was collected by the researcher as necessary for this
project. Prison authorities had no involvement in health record selection or access to the data
collection instruments, logbook, or IBM SPSS database.
Procedure
Protection of Privacy. The privacy of subjects was protected through the
implementation of procedure whereby data were not linked to identifying subject information.
Prior to data collection, copies of the instrument were made. Each copy of the instrument form
had a preprinted subject number according to a list of simple ordinal numbers (1, 2, 3 …). As
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such, the subject number was not linked to inmate name, date of birth, inmate identification
number, housing unit, or social security number.
Confidentiality of Data. Measures to protect the confidentiality of data were
implemented. The list of subject numbers was recorded in a bound logbook and locked in a file
cabinet within a locked office located on the campus of the contracted health care organization
and accessible only to the dissertation advisor and researcher. The preprinted instruments with
subject numbers were kept in a stack according to numerical order as documented in the
logbook. These were kept in the possession of the researcher during transportation between
external sites and the office.
Instruments were retained in a secure University of Connecticut Health Center (UCHC) location
and accessible only to the dissertation advisor and researcher. Following the dissertation
project, the logbook will be destroyed. The instruments will be retained in a secure UCHC
location for a minimum of three years following project completion. Destruction of the logbook
and instruments will consist of document-shredding and disposal through the contracted health
care organization’s existing system of confidential destruction process of secure document
shredding. Data were entered into an IBM SPSS spreadsheet of a password-protected desktop
computer. Access to recorded electronic (IBM SPSS) data was limited to the dissertation advisor,
researcher, and statistician. Following the doctoral dissertation presentation, electronic files of
spreadsheets will be deleted. Any hard copies of files that might have been made will be stored
with project instruments and follow instrument retention and destruction processes as previously
outlined.
Data Management
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Data Collection. Data collection followed a systematic process whereby correctional
facilities were ranked according to the number of adult male inmates estimated to have T2D.
Estimates of facility T2D prevalence consisted of the review of an on-demand electronic
pharmaceutical database report completed prior to project approval.
The electronic pharmaceutical database reported medications filled by the central
pharmacy unit in response to prescriber orders faxed to the pharmacy by facility nursing staff.
As facility automated dispensing units (ADUs) were linked to the pharmacy system, medications
removed by nurses from ADUs were also reported. Database information included inmate
number, inmate name, facility, housing unit, generic medication name, medication dose and
frequency, first pharmacy fill, last pharmacy fill, medication prescriber, and medication category.
This information applied to single-dose, episodic, and chronic medications.
The pharmacy filled medication orders, including oral medications commonly used to
treat T2D, individually and based on specific inmate information. In addition to orders filled by
the pharmacy, a limited supply of medications was stocked in ADUs. The ADUs were used to
supply medications for urgent needs or in advance of orders received from the pharmacy. Nurses
were required to sign out each medication taken from the ADU inventory by individual inmate.
The ADU inventory was directly linked to the electronic pharmaceutical database.
The pharmacy supplied insulin to facilities as an ADU stock medication. When multidose vials were taken from ADU inventory, nurses signed out the total number of vials used
using a facility identifier. As usage was not linked to particular inmates, the pharmacy database
could not be used to obtain an accurate reporting of individual inmate insulin usage. Therefore,
the number of inmates who might currently be administered insulin as sole or part of their T2D
treatment could not be estimated.
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As the electronic database could not be linked to insulin use, the generated
pharmaceutical database report was limited to inmates currently prescribed oral medications
commonly used to treat T2D. Based on this report, approximately 450 inmates could have had
T2D. However, it is possible that medication might have been ordered to treat disorders other
than T2D. As no tracking system existed to link medications with diagnoses, the only way to
determine if medications had been ordered for the management of T2D was to individually
review the paper health records of inmates prescribed these medications.
As it was not known exactly how many inmates within the correctional system had been
diagnosed with T2D during incarceration, it was important to identify as many potential subjects
as possible prior to conducting data collection. To verify potential subjects that had been listed
on the on-demand pharmacy report and identify additional potential subjects that may have not
yet been included on the pharmacy report, Medication Administration Records (MARs) of all
inmates prescribed medication and housed within the facility sampled were reviewed. As MARs
accompany inmates to their receiving facilities when they are transferred, and are updated
following the receipt of new, adjusted, or discontinued medication orders, facility nursing
supervisors and staff nurses regularly assigned to the facility pharmacy deemed that the
information documented on MARs was the most current and accurate source of medication
orders.
The review of MARs commenced at the facility ranked highest in probability based on
the prevalence estimates derived from the pharmaceutical database report. As inmates currently
prescribed medications commonly used to treat T2D were detected, the individual inmate
identification numbers were entered into a bound logbook to correspond with a prepared list of
simple ordinal numbers (1, 2, 3 …). The ordinal numbers were assigned to subjects in
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numerical order. As such, the subject number was not related to inmate name, date of birth,
inmate identification number, housing unit, or social security number. The bound logbook was
locked in a file cabinet in a locked office of UCHC and accessible only to the student researcher
and faculty advisor (principal investigator). The logbook was retained for the duration of the
project including data analysis and presentation of the doctoral dissertation.
Prior to data collection, copies of the data collection instrument were made and numbered
with simple ordinal numbers to correspond with each inmate identification number noted in the
logbook. The preprinted instruments with subject numbers were kept in a stack according to
numerical order as documented in the logbook.
Data were collected through the review of health records corresponding to those of
inmates recorded in the logbook and the prepared collection instruments. If health record
information needed to complete the demographic data elements listed on the instrument was
missing, the data were to be discarded and another health record reviewed to replace it.
Based on the review of MARs at the highest-ranking facility, 232 inmates were identified
as currently taking medications commonly used to treat T2D. The sample of 50 subjects was
derived from the review of 123 health records belonging to potential subjects. If it had been
found that that the sample size 50 had not been attained at the highest-ranking facility, the
process would have proceeded at the next likely facility. This method would continue at
subsequent facilities until the established sample size had been met or all health records of
inmates identified to be taking medications commonly used to treat T2D had been reviewed.
Data Cleansing. Data were entered into an IBM SPSS spreadsheet on a continuous basis.
Each entry was double-checked against the data collection instrument for accuracy.
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The sample of 50 subjects was derived from the review of 123 health records of potential
subjects. Through the review of health records, 9 subjects were found to meet project inclusion
criteria during the first week of data collection, 25 during the second week, and 19 during the
third week for a total of 53. Although the number of subjects meeting criteria was tracked on an
ongoing basis to monitor the status of data collection for the established sample size of 50
subjects, it was not until data for the third week were tabulated was it noted that data from 3
additional potential subjects had been obtained. It was decided to retain these forms in the event
that reexamination of the last week’s data found that any of the data collection forms were
missing demographic data, and therefore could not be used. Reexamination found that it was not
possible to calculate one subject’s BMI as his weight exceeded the limits of the standard graph
(Appendix B). All data for this subject were discarded and replaced with that of the 51st subject.
Due to over-collection, the 52nd and 53rd potential subjects were discarded.
Data Analysis. Type 2 diabetes risk factor analysis was performed using IBM SPSS,
version 19. Only data of inmates who met project criteria (adult males diagnosed with T2D
during incarceration) as identified on the review of health records and had complete
demographic data were entered into the IBM SPSS database and analyzed. Information entered
into the data and variable views of the IBM SPSS project file were checked against the raw data
to ensure that errors in data entry had not been made.
Data were analyzed to measure the number and frequency of selected preexisting major
T2D risk factors in adult male inmates diagnosed with T2D during incarceration. Analyses were
done to estimate the number of those with T2D who had been diagnosed during incarceration
and to describe relationships between the incidence of T2D risk factors and the variables of
race/ethnicity, BMI, and age.
Generalization and Predictions
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As sampling was limited to one facility, the findings of this quality improvement pilot
project cannot be generalized and are therefore limited to the facility where data was obtained.
Following the completion of data collection and analysis, a clinical panel convened to review
these findings against the 2009 NCCHC, 2011 ADA , and 2010 FBOP diabetes guideline
screening recommendations to decide which guideline best addressed T2D risk in the sample.
Summary
Type 2 diabetes screening recommendations in correctional settings differ according to
major risk factor criteria. The guideline that recommends screening of those with risk factors
most commonly associated with disease development within a population would be most
appropriate to target screening. Data concerning the number and frequency of known major T2D
risk factors identified within a sample of inmates diagnosed during incarceration were collected
and described to help facilitate guideline selection and standardize screening within a state
correctional system. By doing so, a clinical panel subsequently proposed a guideline for
implementation as a prospective quality improvement study.

Chapter 4
The findings of this quality improvement pilot project are reported in this chapter. The
method of data analysis was guided by the project’s research questions, which was to initially
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describe the number and frequency of preexisting major T2D risk factors in a sample of adult
male inmates diagnosed with diabetes during incarceration and to subsequently decide which
diabetes guideline screening recommendations best addressed T2D risk in the sample.
Results
Fifty subjects were obtained from the review of 123 health records, excluding 3 health
records corresponding to potential subjects whose data were discarded. Descriptive
characteristics of the sample’s demographic variables are presented in Table 1.
When this pilot project was conducted, approximately 31% of the adult male population
at the project facility was > 45 years of age. Subject age at the time of T2D diagnosis ranged
from 23 to 66 years of age, with the mean age at the time of diagnosis 45.64 (SD 11.07).
Twenty-two (44%) subjects were black, sixteen (32%) were Hispanic/Latino, and twelve (24%)
were white. No subjects were identified as belonging to Asian, Native North American, or Other
racial/ethnic groups. Based on the most recent measured height and weight that had been
documented prior to T2D diagnosis, the sample had a mean BMI of 30.54 (SD 5.85), ranging
from 21 to 49. Forty-three subjects (86%) had a BMI > 25.
The date of incarceration for which T2D diagnosis was made ranged from June 1983 to
April 2011. The mean length of incarceration prior to T2D diagnosis was 37.96 months (SD
60.91), and ranged from 1 to 283 months. Twenty-three (46%) subjects were diagnosed within
12 months of incarceration, fourteen ( 28%) between 14 and 27 months, eight between 34 and
88 months ( 16%), and five between 134 and 283 months ( 10%). The average number of
facilities in which health care was provided during the incarceration period prior to T2D
diagnosis was 3.32 (SD 2.98) and ranged between one and seventeen.
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Table 1
Demographics (N=50).
Characteristic

Mean

SD

Age

45.64

11.07

BMI

30.54

Months Until Diagnosis

95% CI for
Mean

Median

Range

42.50-48.78

44.50

23-66

5.85

28.88-32.20

29.50

21-49

35.74

58.36

19.15-52.33

15.00

1-283

3.32

2.98

2.47-4.17

2.00

1-17

Frequency

Percent

Black

22

44.00

Hispanic/Latino

16

32.00

White

12

24.00

Asian

0

0.00

Native American

0

0.00

Other

0

0.00

Number of Facilities
Race/Ethnicity

Descriptive characteristics of the T2D risk factor variables are presented in Table 2.
A total of thirteen (26%) diabetics were found to have a preexisting history of impaired fasting
glucose (prediabetes). Thirteen had been identified through a calculated fasting blood glucose
(FBG) measurement of 110 to 125 mg/dl. Of these, only three subjects had concurrent
glycosylated hemoglobin (HgbA1c) testing. HgbA1c results for these subjects ranged from 5.7
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to 6.4. No subjects were identified as having HgbA1c testing in the absence of concurrent FBG
testing.
Nine (18%) subjects were found to have a preexisting history of dyslipidemia. Of these,
seven (14%) had been prescribed lipid lowering medication or had a high density lipoprotein
(HDL) measurement < 35 in addition to a fasting serum triglyceride level > 250, one (0.02%)
had a fasting HDL without a fasting serum triglyceride level > 250, and one (0.02%) had a
fasting serum triglyceride level > 250 without a fasting HDL < 35.
Four (8%) subjects had a current or previous history of coronary vascular disease.
Nineteen subjects (38%) met one or more diagnostic criteria for hypertension (medication
therapy or most recent SBP > 140 or DBP > 90 with > 3 consecutive measurements SBP 135 or
DBP > 80). Seventeen (34%) had a history of antihypertensive therapy, a most recent systolic
blood pressure (SBP) measurement of > 140, or diastolic blood pressure (DBP) measurement of
> 90. Four subjects (8%) had three or more consecutive treated or untreated SBP measurements
of > 135 or DBP > 80. Two subjects belonging to this elevated blood pressure group had been
prescribed antihypertensive therapy.

Table 2
Type 2 Diabetes risk factors (N=50)

Running head: DIABETES SCREENING IN INMATES

49
Frequency

Percent

Age > 45

27

54.00

BMI > 25

43

86.00

Cardiovascular Disease

4

8.00

Dyslipidemia: Total

9

18.00

Fasting HDL < 35 and Fasting Serum Triglycerides > 250

7

14.00

Fasting HDL < 35

1

0.02

Fasting Serum Triglycerides > 250

1

0.02

38

76.00

40

80.00

Most Recent SBP >140 or DBP >90 and >3 consecutive
measurements SBP >135 or DBP >80

19

38.00

Most Recent SBP >140 or DBP >90

17

34.00

4

8.00

13

26.00

10

20.00

Fasting Blood Glucose: 110 – 125 without HgbA1c testing

0

0.00

HgbA1c: 5.7 - 6.4 without Fasting Blood Glucose testing)

3

6.00

Risk Factor

High Risk Racial/Ethnic Group: Total
Black, Hispanic/Latino, Native American, or Asian
Hypertension: Total

Three consecutive measurements SBP >135 or DBP >80)
Impaired Fasting Glucose (Prediabetes): Total
Fasting Blood Glucose: 110 - 125 and HgbA1c: 5.7 - 6.4

Clinical Panel Findings
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A clinical panel consisting of the medical directors of the correctional system and
contracted health care provider and a community-based certified diabetes educator with expertise
in treating inmates following incarceration met to review the T2D screening recommendations of
the three guidelines and data from the pilot project. The three guidelines considered were:
Diabetes Management in Correctional Institutions (ADA, 2011b), Federal Bureau of Prisons
Diabetes Practice Guidelines (FBOP, 2010), and National Commission on Correctional Health
Care Diabetes Management Guidelines (NCCHC, 2009).
Based on their review, the members of the clinical panel agreed that its selection of a
guideline could be based on their review of the four most common T2D risk factors that had
been identified: BMI > 25 (86%; n=43), belonging to a high risk racial/ethnic group (76%;
n=38), age > 45 (54%; n=27), and a history of hypertensive medication therapy or a most recent
SBP measurement of >140 or a DBP measurement of > 90 (34%; n=17). The group also agreed
that mean age (45.64) and BMI (30.54) at the time of T2D were important findings.
Clinical Guidelines
The Federal Bureau of Prisons Diabetes Practice Guidelines. The clinical panel
reviewed the Federal Bureau of Prisons (FBOP, 2010) diabetes practice guidelines and rejected it
for several reasons. These guidelines recommended routine diabetes screening only for low-risk
inmates who have a treated or untreated blood pressure > 135/80. Otherwise, these guidelines
advised T2D screening as part of the management of disease states as clinically appropriate
(FBOP, 2010).
Based on the 2010 FBOP recommendation to screen asymptomatic inmates having
treated or untreated SBP 135 or DBP > 80, only 8% (n=4) of subjects would have been screened
for T2D. The panel deemed that based on this criterion alone, many inmates with T2D might not
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be screened. The panel also felt that direction to conduct T2D screening as part of the
management of disease states as clinically appropriate provided insufficient guidance to
standardize screening within the state’s correctional system.
The American Diabetes Association Standards of Care. The ADA’s Diabetes
Management in Correctional Institutions (ADA, 2011b) recommended conformity to the ADA
Standards of Care. Based on these standards, screening in adult male inmates should be
considered in those having a BMI of > 25 and with at least one additional T2D risk factor: highrisk race/ethnicity, current antihypertensive therapy or blood pressure > 140/90, impaired fasting
glucose/ prediabetes, dyslipidemia, cardiovascular disease, a first-degree relative with diabetes,
or physical inactivity. In absence of any of the named risk factors, the ADA advises T2D
screening for individuals > 45 years of age (ADA, 2011a).
The clinical panel noted that 84% (n=42) of subjects in the sample would have been
screened for T2D based on the BMI > 25 with one additional risk factor criterion (Table 3).
Dyslipidemia based on the 2010 ADA criterion of Fasting HDL < 35 or Fasting Serum
Triglycerides > 250 was not a primary risk factor in the sample population with only 14% (n=7)
of subjects found with a prior history. Although the group had expected that the findings would
be more significant, only 26% (n=13) of subjects were found to have a history of impaired
fasting blood glucose (prediabetes) based on ADA HgbA1c (5.7 - 6.4) or Fasting Blood Glucose:
(110 – 125) criterion.
The clinical panel noted that data for major T2D risk factors named by ADA, primarily
physical inactivity and first-degree relative with diabetes, had not been collected for this pilot
project. It was explained this information was not collected as it had not been routinely
documented in the health record by health care staff the data were unavailable. Subsequently, the
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clinical panel decided to compare the remaining variables against the National Commission on
Correctional Health Care (NCCHC, 2009) Diabetes Management Guidelines prior to making its
recommendation.
The National Commission on Correctional Health Care Diabetes Management
Guidelines. In comparison to the ADA which recommends T2D screening for those having
another major T2D risk factor in addition to BMI > 25, the National Commission on
Correctional Health Care (NCCHC, 2009) guideline allowed for screening based on individual
major risk factors. The diabetes management guideline issued by NCCHC recommended routine
T2D screening for inmates having at least one T2D risk factor. Major T2D risk factors included
overweight/obese (BMI > 25), history of hypertension or dyslipidemia, and age 45 or more
(NCCHC, 2009, p.1). NCCHC criteria for hypertension and dyslipidemia were the same as those
of the ADA.
Applying 2009 NCCHC criteria to the major T2D risk factors described, 98% (n=49) of
the sample subjects would have been identified for screening. Comparatively, the number of
those who would have been identified for T2D screening using ADA criteria (84%, n=42) or
FBOP hypertension criterion (8%, n=4) would have been less. Based on this observation, the
clinical panel determined that the NCCHC guideline had the greatest potential for identifying
inmates who might benefit from screening. Panel members also commented that the clarity by
which the NCCHC guideline defined and targeted risk factors would best help standardize T2D
screening if future study findings support statewide implementation.
The panel members found that implementation of any of the three guidelines would help
target screening. Although the pilot project was limited to one facility, given the findings that
approximately 41% of 123 health records reviewed yielded a sample of 50 subjects (40.6%), and
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46% (n=21) of these subjects had been diagnosed within 12 months of incarceration, the panel
remarked that the incidence of T2D diagnosed during incarceration could potentially be
significant. Given this, the panel supported standardized targeted T2D screening. Based on its
review of risk factor data, the panel decided that the recommendations of the NCCHC guideline
best addressed T2D risk in the sample. Implementation of this guideline as a prospective quality
improvement study in a broader sample was proposed prior to considering statewide application.

Table 3
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Inmates with T2D who would have been screened based on guideline criteria.
Screening Guideline
ADA

Criteria for T2D Screening

BMI > 25 with one additional risk factor

Frequency

Percent

42

84.00

49

98.00

4

8.00

10

20.00

Age > 45
High Risk Ethnicity
Cardiovascular Disease
Hypertension ( Medication Therapy or Most
Recent SBP >140 or DBP >90)
Dyslipidemia (Fasting HDL < 35 or Fasting
Serum Triglycerides > 250)
Impaired Fasting Glucose (HgbA1c: 5.7 - 6.4
or Fasting Blood Glucose: 110 – 125)
NCCHC

Any of the below risk factors:
Age > 45
BMI > 25
Hypertension Medication Therapy or Most
Recent SBP >140 or DBP > 90)
Dyslipidemia(Fasting HDL < 35 or Fasting
Serum Triglycerides > 250)

FBOP

Treated or Untreated ( > 3 consecutive
measurements) SBP 135 or DBP > 80)
Otherwise, those with dyslipidemia or other disease
states as clinically appropriate
Cardiovascular Disease
Dyslipidemia (Fasting HDL < 35 or Fasting
Serum Triglycerides > 250)

Summary
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The purpose of this quality improvement pilot project was to facilitate standardized T2D
screening of inmates within a correctional system. Following a retrospective review of health
records belonging to a sample of inmates diagnosed with T2D during incarceration at one of
correctional system’s facilities, the number and frequency of major risk factors were described.
A clinical panel reviewed the project’s findings, compared three diabetes management
guidelines, and decided that that the screening recommendations within the NCCHC diabetes
management guideline best addressed T2D risk within the sample. Implementation of the
NCCHC guideline as a prospective quality improvement study in a broader sample was
proposed prior to considering statewide application.

Chapter 5
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This quality improvement pilot project was undertaken to improve T2D screening within
a state correctional system by selecting one guideline to standardize screening. The number and
frequency of selected T2D risk factors within a sample obtained from one correctional facility
were described. The data derived from this sample was reviewed by a clinical panel which
proposed the guideline that best addressed T2D risk in that sample. Implementation as a
prospective quality improvement study in one or more correctional facilities was advised prior to
considering statewide application. The information from this project can also be used to plan
inmate education programs aimed to address reversible T2D risk factors.
The sample consisted of 50 adult male inmates who had been diagnosed with T2D during
incarceration. A retrospective health record review was done using a data collection instrument
created to document demographic and selected major T2D risk factor derived from
recommendations of the CPGs being considered for implementation and which were retrievable
from the inmate health record. As it was not known how many of the correctional system’s
diabetic inmates had been diagnosed with T2D during incarceration, facilities were ranked by the
estimated number of those diagnosed with T2D. The intent was to start data collection at the
highest-ranking facility and continue until the established sample size was obtained. The sample
size was unexpectedly attained at the first facility in which data collection was undertaken.
Sample size and design limited generalizability to the correctional facility where the
sample was obtained, and the clinical panel that reviewed the project’s findings decided which
screening recommendations best addressed T2D risk in the sample. Implementation as a
prospective quality improvement study in a broader sample was recommended prior to statewide
application. The panel considered the screening recommendations of three diabetes management
guidelines: the 2011 American Diabetes Association’s (ADA) Diabetes Management in
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Correctional Institutions, the 2010 Federal Bureau of Prisons (FBOP) Diabetes Practice
Guidelines, and the 2009 National Commission on Correctional Health Care (NCCHC) Diabetes
Management Guidelines. Based on the finding that application of NCCHC guideline
recommendations to major risk factors identified in the sample would yield screening in 98%
(n=49) of the sample, which exceeded both the ADA (84%, n=42) and FBOP recommendations
(8%, n=4 based on hypertension criteria; 20%, n=14 based on cardiovascular or dyslipidemia
criteria) recommendations, the panel selected the NCCHC guideline for future implementation.
The findings of this pilot project were also shared with the state department of correction
administration for anticipated program planning aimed to address reversible T2D risk factors.
Discussion of Findings
A sample size of 50 subjects was selected for this quality improvement pilot project as it
was believed that this would be sufficient for the purpose of the project. It was not known as to
how many inmates with T2D had been diagnosed during incarceration. Anticipating that
sampling of up to 450 health records might be needed to attain the sample size, it was projected
that sampling would be done at several or more of the state correctional facilities which would
have been representative of the state system. Obtaining the entire sample at the facility ranked
highest for the estimated number of diabetic inmates was an unexpected finding. Also
unexpected was the finding that the sample was obtained from a review of 123 records of
inmates who potentially met inclusion criteria. Data belonging to one inmate who did not meet
inclusion criteria (BMI could not be calculated using the selected instrument), and two inmate
records that were discarded as sample size had been attained, were not entered into the database.
For statistical and data cleansing tracking purposes, it would have been appropriate to have
entered these data into the SPSS database.
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Twenty-three (46%) of the subjects in the sample were diagnosed with T2D within 12
months of incarceration and 10% at or following 134 months of incarceration. Over half (54%)
of those in the sample were 45 years of age or more at the time T2D was diagnosed. In
comparison, approximately 20% of the correctional system’s total adult male inmate population
and 31% of inmates incarcerated at the facility where the sample was obtained were 45 years of
age or more. The observation that the percentage of inmates at the facility where the sample was
obtained estimated to be over age 45 exceeded that of the correctional system’s total adult male
population may be reflective of the correctional system’s practice of cohorting inmates based on
medical needs inclusive of age-related disabilities.
The review of the literature did not find studies that reported the relationship between
BMI and T2D in the correctional population, and BMI data were unavailable for the total
populations of the sample facility and state correctional system where the project was done.
Therefore, the significance of finding 86% of subjects with a BMI of 25 or higher prior to T2D
diagnosis is unknown. According to data reported by the Bureau of Justice Statistics (BJS)
approximately 56% of all national prisoners would meet criteria for the high T2D racial/ethnic
group (West, et al., 2010). In comparison, approximately 73% (n=15,956) of the state
correctional system’s total adult male population, 64% (n=1527) of the sample facility’s adult
male population, and 76% (n=38) of those in the sample met high T2D racial/ethnic group
criteria.
A noticeable percentage (44%, n=22) of those in the sample were found to have multiple
T2D demographic risk factors, specifically BMI over 25 and age 45 or more. As BMI tends to
increase with age, and both are major T2D risk factors, this finding was not surprising. Thirty
percent (n=7) of those with a BMI over 25 and age 45 or more also belonged to a high-risk
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racial/ethnic group. As the majority of the sample facility population belonged to a high T2D
racial/ethnic risk group, this finding was also not surprising.
The percentages of those in the sample found to have a history of impaired fasting
glucose (prediabetes), hypertension, and cardiovascular disease exceeded respective projection
estimates reported in the literature. The overall percentage of those (26%, n=13) with preexisting
impaired fasting glucose (prediabetes) was over four times that of the prevalence projection
(4.8%) for the total prison inmate population reported by Hornung et al. (2002). Compared with
the 38% (n=19) of subjects in the sample found to have preexisting hypertension, overall
prevalence estimates by Wilper et al. (2009) and Binswanger et al. (2009) were 31% and 30%
respectively. Against the 8% (n=4) of those in the sample who were identified to have current or
previous history of coronary vascular disease, pooled data derived from the projection estimates
reported by Binswanger et al. (2009) approximates projected prevalence for cardiovascular
disease at 3%. No projection estimates were found in the literature reviewed specific to
dyslipidemia in the inmate population.
Although comparisons between the frequencies of T2D risk factors described in this
quality improvement pilot project and disease conditions reported in projection estimates are
reported, due to variations in sample size, data collection methods, and statistical analysis, the
relevance of these findings is limited. Prevalence estimates reported in the literature in the
correctional setting were heavily based on existing self-reporting survey data and it is possible
that disease conditions were underreported. Other reasons for variations between the measured
risk factor frequencies found in this of this pilot project and reported prediction estimates might
include variations in age demographics and comorbidities.
Limitations
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Due to limitations, the results of this quality improvement pilot project are generalizable
only to adult male inmates diagnosed with T2D during incarceration and confined to the one
correctional facility where the project was conducted. These limitations included limiting the
sample to adult male inmates, obtaining the sample from one facility, and the inability to report
the frequency of additional major T2D risk factor data (i.e. physical inactivity, first-degree
relative with diabetes, acanthosis nigricans) data due to inadequacies in obtaining, documenting,
or integrating information in the current inmate health record.
Although not collecting data belonging to female and adolescent males was believed
appropriate based on small sample estimates of T2D in these populations, limiting the sample to
adult males caused sampling bias. Unintentional sampling bias subsequently occurred through
the process whereby subjects were selected. Even though facilities had been ranked according to
the probability of subjects meeting the inclusion criteria, it had not been anticipated that the
entire sample would be obtained from the population of a single facility.
A sample size of 50 subjects had been deemed adequate for this pilot project as it was not
known how many inmates within the correctional system had been diagnosed with T2D during
incarceration and a descriptive design was planned to report quantitative data. Surprisingly, this
sample was obtained from the review of 123 health records belonging to inmates housed at the
first facility where data were collected. Based on statistical analysis, 40.2% of the inmates
whose records were reviewed had been diagnosed with T2D during incarceration. Although
further analysis suggested that the standard error for the estimated prevalence rate would have
been relatively precise regardless of the number of records reviewed at the facility where the
sample was obtained, this estimate may not be representative of all inmates diagnosed with T2D
during incarceration within the state correctional system. It is possible that the system’s practice
to consider inmate medical needs when determining housing placements resulted in a
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disproportionate number of inmates with or at high risk for developing T2D during incarceration
being housed at the facility sampled. If these subjects had substantial comorbidities, the
prevalence of major T2D diabetes risk factors of inmates included in this sample could have
been greater than those of potential subjects housing inmates with less complex medical needs.
Because information not routinely obtained by health services staff or documented in the
inmate health record could not be collected, frequencies of other major T2D risk factors named
in diabetes guideline screening recommendations (i.e. physical inactivity, first-degree relative
with diabetes, acanthosis nigricans) were not obtained. Also, as the sample excluded female
inmates, the frequency of additional major T2D risk factors specific to females (i.e. history of
gestational diabetes, polycystic ovarian disease, or having delivered a baby weighing > 9
pounds) was not reported. Descriptions of less-powerful and less prevalent T2D risk factors (i.e.
history of atypical antipsychotic medication therapy, psychosis, human immunodeficiency viral
infection, low socioeconomic level, less than high school education, and health illiteracy) were
not considered because they were not named major T2D screening risk factors in the
recommendations of the screening guidelines reviewed.
Several factors encompassing the documentation of major T2D risk factors might have
resulted in underreporting frequency for these conditions. These factors include the integrity of
the existing paper inmate health record and lack of consistent T2D screening prior to or during
incarceration.
As data collection was limited to that found in the health record, and as the correctional
system utilized a paper inmate health record, T2D risk factor information could have been
documented incorrectly or incompletely, misread, or missing. Reasons for this include misfiling
and illegible handwriting. As a mechanism did not exist to identify inmates who would have
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meet inclusion criteria but were being treated with dietary restrictions alone, these inmates were
not included in the sample. The risk for underreporting could have been decreased if an
electronic health record (EHR) had been in use for documentation and tracking purposes.
Implications and Recommendations
As with the community population, the incidence of T2D in inmates is expected to
increase. Socioeconomic costs associated with T2D and its complications are significant.
Although screening may prevent or delay the onset of T2D, universal screening has been shown
not to be cost effective and is not recommended (Chatterjee et al., 2013; Hoerger et al., 2004).
By describing selected T2D major risk factors identified in a sample of those diagnosed during
incarceration, a clinical panel recommended the 2009 NCCHC Diabetes Management Guideline
for implementation as a prospective quality improvement study. Increasing sample size,
sampling across multiple facilities, including subjects belonging to female and adult youth
groups, randomly selecting subjects that meet inclusion criteria statewide, and obtaining data for
those major risk factors that had not been reported would help report major T2D risk factor data
that s are more representative of the entire correctional system. In addition, as the prevalence of
less-powerful T2D risk factors may be greater in the correctional population than in the
community, reporting the frequency of these risk factors may justify additional conditions for
which targeting might be studied.
Implementation of an electronic health record (EHR) would help ensure more complete,
accurate, and timely documentation of inmate health histories and assessments and support data
retrieval. A direct link to the pharmacy database would be useful to retrieve the most current
medication prescription information. Links to custody information concerning inmate level of
education, socioeconomic status prior to incarceration, work and recreation history, and
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commissary usage would allow ready access to information relative to health promotion.
Additionally, an EHR would facilitate the review and collection of data pertaining to large
samples across and between correctional facilities.
In addition to implementing measures to control limitations identified in the completed
project, an important concern that should be addressed in the design of future T2D quality
improvement initiatives is the potential number of inmates who might be at risk for T2D but are
just below the selected guideline’s BMI and age screening parameters. A possible solution
might be to shorten the screening interval time for those inmates meeting one or more of these
criterion.
Summary
The aim of this quality improvement pilot project was to facilitate standardized T2D
screening of inmates within a correctional system, specifically, to describe the number and
frequency of selected major T2D risk factors in a sample of inmates diagnosed with T2D during
incarceration for review by a clinical panel tasked with identifying the guideline screening
recommendations that best addressed T2D risk in the sample. A data collection instrument was
developed to document risk factor and related information and to facilitate the sample selection
process. Following its review of prevalence data of preexisting major T2D risk factors in a
sample of inmates diagnosed with T2D during incarceration, a clinical panel recommended the
2009 NCCHC screening guideline for future implementation as a prospective quality
improvement study.
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Date of Health record Review (m/d/yr):____/____/_____

Subject ID (Simple ordinal number [1,2,3…]in numerical order) : ________________
Age (in years): ______

Month/Year of Incarceration: ______ /______

Height (in inches): ______ Weight (in pounds): ______
Race (check one): Caucasian (White)
Native American
Section Criteria

Calculated BMI :________

African/American (Black)
Hispanic/Latino
Asian
Other _________________
No
Yes
(If No, Stop Here)

(if Yes
proceed to
next
question)

Diagnosed with diabetes?
Diagnosed during incarceration?
Diagnosed with T2D?
Month/Year of T2D Diagnosis (relevant only if diagnosed during
incarceration):
Number of CDOC facilities the subject received medical services from prior to
T2D diagnosis (limited to the admission in which the diagnosis was made):
Major T2D Risk Factors Prior to T2D Diagnosis?
Age >45?
BMI > 25?
On lipid lowering medication or documented fasting high density lipoprotein
level of 35 or less?
On lipid lowering medication or documented fasting serum triglyceride level
>250 mg?
Documented history of impaired fasting glucose/prediabetes (HgbA1c 5.7 to
6.4)?
Documented history of impaired fasting glucose/prediabetes (fasting glucose
110 to 125 mg/dl)?
Belonging to a high risk racial/ethnic group (Black, Hispanic/Latino, Native
North American, or Asian)?
Documented current or past history of coronary vascular disease?
On antihypertensive therapy or most recent documented SBP > 140 or DBP
>90?
Sustained (3 or more consecutive treated or untreated BP measurements) SBP
> 135 or DBP >80
Comments:
Appendix B

/

No

Yes
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